Effect of Dose Adjustments on the Safety and Efficacy of Afatinib in Chinese Patients with EGFR-Mutated Non-Small Cell Lung Cancer Who Participated in the LUX-Lung Clinical Trial Program

BACKGROUND: Post hoc analysis of the LUX-Lung 3 and 6 (LL3/6) Phase III trials showed that tolerability-guided dose-adjustments of afatinib reduced treatment-related adverse events (TRAEs) without affecting progression-free survival (PFS) in patients with epidermal growth factor receptor (EGFR) muta...

Descripción completa

Detalles Bibliográficos
Autores principales: Tu, Hai-Yan, Wu, Yi-Long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7733053/
https://www.ncbi.nlm.nih.gov/pubmed/33324072
http://dx.doi.org/10.2147/OTT.S273866

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7733053/
https://www.ncbi.nlm.nih.gov/pubmed/33324072
http://dx.doi.org/10.2147/OTT.S273866

Ejemplares similares